P33.15 TMB in the First-Line Setting of NSCLC: A Systematic Review with Indirect Comparisons Between PD-1 and PD-L1 Inhibitors

Tumor mutational burden (TMB) has been deeply investigated either on tissue or blood as immune checkpoint inhibitors (ICIs) positive predictive biomarker in the frontline setting of advanced Non-Small Cell Lung Cancer (NSCLC). However, the clinical utility of TMB for identifying patients who may benefit from ICIs remains unclear.